Lupin launches HIV drug in US, secures eligibility for 180-day generic exclusivity

What happened

Lupin launched Raltegravir Tablets USP, 600 mg, in the United States after FDA approval of its Abbreviated New Drug Application. Lupin is the exclusive first-to-file and is eligible for 180-day generic drug exclusivity. The drug is bioequivalent to Merck's Isentress HD and treats HIV-1.

Confirmed

Global impact / market context

The 180-day exclusivity gives Lupin a protected selling window before other generic versions can enter, which can support higher sales and profit per sale during that period. IQVIA data cited in the article estimates annual US sales of $26 million for this product.

Confirmed

This follows Lupin's approval a day earlier for Amifampridine Tablets with 180-day shared exclusivity, showing a run of US generic approvals. Two first-to-file wins close together may raise investor attention to Lupin's US pipeline, though the Raltegravir market cited is modest in size.

Analyst inference

What to watch

1. Watch Lupin's US launch progress for Raltegravir 600 mg, since the article states 180-day generic exclusivity is exclusive to Lupin for this product. Confirmed
2. Watch whether the 180-day exclusivity period translates into visible sales growth, given the article's $26 million annual US sales estimate; that revenue flows to Lupin only if it captures prescriptions from Merck's branded Isentress HD. Analyst inference
3. Watch for updates on Lupin's separate Amifampridine approval and shared exclusivity, since the article does not state when that product will launch commercially. Analyst inference

Evidence

• Original source link unavailable